Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Pfizer, Inc.
  6. News
  7. Summary
    PFE   US7170811035

PFIZER, INC.

(PFE)
  Report
Real-time Estimate Cboe BZX  -  05/25 04:04:43 pm EDT
53.40 USD   -0.02%
12:33pPfizer to offer low-cost medicines, vaccines to poor nations
AQ
12:17pGLOBAL MARKETS LIVE : Glencore, Starbucks, Apple, Lyft, Intuit...
10:47aPfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Canada has approved Pfizer's COVID-19 oral antiviral treatment - government website

01/17/2022 | 10:10am EDT
share with twitter
share with LinkedIn
share with facebook

Jan 17 (Reuters) - Pfizer Inc:

* CANADA HAS APPROVED PFIZER'S COVID-19 ORAL ANTIVIRAL TREATMENT - GOVERNMENT WEBSITE Source text for Eikon: Further company coverage: (Reporting by David Ljunggren)


© Reuters 2022
All news about PFIZER, INC.
12:33pPfizer to offer low-cost medicines, vaccines to poor nations
AQ
12:17pGLOBAL MARKETS LIVE : Glencore, Starbucks, Apple, Lyft, Intuit...
10:47aPfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-..
AQ
10:19aWALL STREET STOCK EXCHANGE : Investors are eagerly awaiting the Fed minutes
10:02aPfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare ..
BU
08:36aPFIZER INC : Goldman Sachs reiterates its Neutral rating
MD
07:33aPfizer Launches Initiative to Sell Medicines, Vaccines to 45 Low-Income Countries on a ..
MT
06:29aMARKETSCREENER'S WORLD PRESS REVIEW : May 25, 2022
06:00aDavos updates | Zelenskyy says Ukraine won't give up land
AQ
03:37aPfizer to Make Patented Treatments Available at Cost in Lower-Income Countries
MT
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 104 B - -
Net income 2022 35 662 M - -
Net cash 2022 15 298 M - -
P/E ratio 2022 8,91x
Yield 2022 3,04%
Capitalization 300 B 300 B -
EV / Sales 2022 2,74x
EV / Sales 2023 3,65x
Nbr of Employees 79 000
Free-Float 58,2%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 53,41 $
Average target price 57,66 $
Spread / Average Target 7,96%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-9.55%299 678
JOHNSON & JOHNSON6.04%477 336
ROCHE HOLDING AG-12.57%281 309
ELI LILLY AND COMPANY10.77%275 413
ABBVIE INC.10.13%263 494
NOVO NORDISK A/S1.61%244 637